Business Wire

Prosimo Announces General Availability of AWS Cloud WAN Integration

12.7.2022 20:52:00 EEST | Business Wire | Press release

Share

Prosimo, the Application Experience Infrastructure company, today announced the general availability of its integration with AWS Cloud WAN. This comes on the heels of AWS announcing today the general availability of AWS Cloud WAN. AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005998/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs. (Graphic: Business Wire)

"With these new features and functionality on the AXI Platform, Prosimo will be ideally suited to meet our goals: enable modern infrastructure capabilities using newer AWS networking constructs such as Cloud WAN, built-in observability for applications, and remove as much complexity as possible,” said Kevin Paige, CISO, Flexport

Enterprises can now simplify how they build and manage connectivity of their disparate environments across AWS regions across the globe, on-premises data centers, colocation facilities, branch offices, and their distributed user base with the combination of AWS Cloud WAN and Prosimo:

  • Achieve fine-grained elastic segmentation – The global network policy in AWS is kept coarse-grained and straightforward by design to be easy to manage and does not change that frequently. Fine-grained policy-based segmentation and security is the requirement from the application teams, in addition to the network layer segmentation. Prosimo helps to build policies at the per user and per-application level, on top of global network segments from Cloud WAN.
  • Hassle-free connectivity from AWS to any cloud – Regardless of how customers approach the core network policy, they will seek to achieve similar hassle-free connectivity to any of their DCs, other cloud providers, and edge co-locations. Prosimo helps extend the same core network policy model with segmentation to any cloud, including on-prem locations.
  • Modern cloud / NetDevOps operational model – Internal constituents such as modern cloud or NetDevOps teams will achieve a higher change frequency. With Prosimo’s APIs and Terraform modules, enterprise teams can integrate with their CI/CD flows for more agile development and deployment models while adhering to security and compliance guardrails and maintaining operational consistency.

Related Link: Sign up directly from the AWS Marketplace .

AWS Cloud WAN furthers Autonomous Multi-cloud Networking Solution

To ensure their multi-cloud environment is consistent, and easy-to-use, enterprises need to build an intelligent fabric that automatically connects applications, services, and networks across cloud infrastructures based on pre-set operations, security, and performance requirements. This requires first solving cloud connectivity issues then building an app transit layer that is autonomous and machine-driven to mitigate inherent complexity. Combining Network Transit and App Transit in a single architecture that simplifies and, most importantly, automates multi-cloud networking.

One Platform to Rule Them All

The combined network transit and app-to-app transit create a Full Stack Cloud Transit built on cloud-native constructs to take advantage of AWS’s global presence including AWS Cloud WAN. This gives enterprises a simpler connectivity model to migrate and connect their brownfield cloud deployments to deliver consistent, reliable, and secure Zero Trust-driven networks to support business-critical and latency-sensitive applications for users in any location.

“Our deepening relationship with AWS reflects the growing interest from AWS customers for simplified cloud networking solutions beyond just connectivity,” said Mani Ganesan, Head of Products, Prosimo. “AWS Cloud WAN and Prosimo offer a seamless and tightly integrated autonomous cloud networking solution as enterprises continue their enterprise cloud journeys and modernize their infrastructure.”

Resources

Connect with Prosimo

About Prosimo:

Prosimo delivers simplified multi-cloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst and WRVI Capital. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press and Analyst Contact:
Matt Stubbs
Outside Labs for Prosimo
(801) 703-6626
press@prosimo.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye